KR100614212B1 - 피이지-유레이트 옥시데이즈 접합체 및 그의 이용 - Google Patents

피이지-유레이트 옥시데이즈 접합체 및 그의 이용 Download PDF

Info

Publication number
KR100614212B1
KR100614212B1 KR1020047014428A KR20047014428A KR100614212B1 KR 100614212 B1 KR100614212 B1 KR 100614212B1 KR 1020047014428 A KR1020047014428 A KR 1020047014428A KR 20047014428 A KR20047014428 A KR 20047014428A KR 100614212 B1 KR100614212 B1 KR 100614212B1
Authority
KR
South Korea
Prior art keywords
peg
freeze
kda
tetramer
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047014428A
Other languages
English (en)
Korean (ko)
Other versions
KR20040088585A (ko
Inventor
엘. 데이비드 윌리엄스
마이클 에스. 허쉬필드
수전 제이. 켈리
마아크 지. 피. 사이퍼
메리 알. 셔먼
Original Assignee
마운틴 뷰 파마슈티컬즈 인크.
듀크 유니버서티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마운틴 뷰 파마슈티컬즈 인크., 듀크 유니버서티 filed Critical 마운틴 뷰 파마슈티컬즈 인크.
Publication of KR20040088585A publication Critical patent/KR20040088585A/ko
Application granted granted Critical
Publication of KR100614212B1 publication Critical patent/KR100614212B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020047014428A 1998-08-06 1999-08-02 피이지-유레이트 옥시데이즈 접합체 및 그의 이용 Expired - Fee Related KR100614212B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13039298A 1998-08-06 1998-08-06
US09/130,392 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-7001569A Division KR100488848B1 (ko) 1998-08-06 1999-08-02 피이지-유레이트 옥시데이즈 접합체 및 그의 이용

Publications (2)

Publication Number Publication Date
KR20040088585A KR20040088585A (ko) 2004-10-16
KR100614212B1 true KR100614212B1 (ko) 2006-08-21

Family

ID=22444494

Family Applications (2)

Application Number Title Priority Date Filing Date
KR10-2001-7001569A Expired - Fee Related KR100488848B1 (ko) 1998-08-06 1999-08-02 피이지-유레이트 옥시데이즈 접합체 및 그의 이용
KR1020047014428A Expired - Fee Related KR100614212B1 (ko) 1998-08-06 1999-08-02 피이지-유레이트 옥시데이즈 접합체 및 그의 이용

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR10-2001-7001569A Expired - Fee Related KR100488848B1 (ko) 1998-08-06 1999-08-02 피이지-유레이트 옥시데이즈 접합체 및 그의 이용

Country Status (13)

Country Link
EP (1) EP1100542B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP5183836B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100488848B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU770014B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI9917760B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ303751B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU228916B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL141220A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ509595A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL220873B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (3) RU2278680C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW570981B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000007629A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT1100880E (pt) 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
EP1588716B1 (en) 1998-08-06 2011-02-16 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
RU2278680C2 (ru) * 1998-08-06 2006-06-27 Маунтэн Вью Фармасьютикэлз, Инк. Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом
AU2006203252B8 (en) * 2000-02-10 2009-06-18 Duke University Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP1279406A4 (en) 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
EP1317258B1 (en) * 2000-06-28 2009-02-11 Merck & Co., Inc. Use of allopurinol for the treatment of hypertension
AU2002345938A1 (en) 2001-06-28 2003-03-03 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
HRP20120989T1 (hr) 2003-05-12 2013-01-31 Affymax, Inc. Peptidi koji se vežu za receptor eritropoetina
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
AU2006235495B2 (en) 2005-04-11 2012-04-12 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
SG161248A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc A variant form of urate oxidase and use thereof
CA2607953A1 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
KR101288027B1 (ko) 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
JP4890132B2 (ja) * 2006-07-20 2012-03-07 東洋紡績株式会社 ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ
RU2382048C1 (ru) * 2008-12-25 2010-02-20 Общество С Ограниченной Ответственностью "Фармапарк" Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием
EP2446260B1 (en) 2009-06-25 2018-12-26 Horizon Pharma Rheumatology LLC Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
US9744175B2 (en) 2012-04-06 2017-08-29 Indus Pharmaceuticals, Inc. Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
WO2016187026A1 (en) 2015-05-15 2016-11-24 Medimmune, Llc Improved uricase sequences and methods of treatment
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
KR20250011715A (ko) 2017-03-11 2025-01-21 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
CN112980808B (zh) * 2019-12-12 2024-10-29 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
EP4240423A1 (en) 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CN114438047B (zh) * 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
US20240060063A1 (en) 2021-02-10 2024-02-22 Oriental Yeast Co., Ltd. Uricase activator and uric acid measurement reagent
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1529675A (fr) * 1967-03-29 1968-06-21 Applic Biochimiques Soc Et Urate oxydase à haute activité et sa préparation
US3616231A (en) * 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6031472B2 (ja) * 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
JPS55135590A (en) * 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
RU2278680C2 (ru) * 1998-08-06 2006-06-27 Маунтэн Вью Фармасьютикэлз, Инк. Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом
PT1100880E (pt) * 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Also Published As

Publication number Publication date
JP2009254376A (ja) 2009-11-05
IL183948A0 (en) 2007-10-31
BRPI9912974B1 (pt) 2015-08-25
CZ303751B6 (cs) 2013-04-24
JP5291235B2 (ja) 2013-09-18
JP5290901B2 (ja) 2013-09-18
PL346224A1 (en) 2002-01-28
HU228916B1 (en) 2013-06-28
PL383331A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-01-28
IL141220A (en) 2007-09-20
EP1100542B1 (en) 2005-06-22
JP5183836B2 (ja) 2013-04-17
WO2000007629A3 (en) 2000-06-08
IL141220A0 (en) 2002-03-10
RU2349341C2 (ru) 2009-03-20
RU2246318C2 (ru) 2005-02-20
IL183948A (en) 2010-11-30
AU5251599A (en) 2000-02-28
NZ509595A (en) 2004-02-27
PL202799B1 (pl) 2009-07-31
KR20040088585A (ko) 2004-10-16
CZ2001317A3 (cs) 2001-07-11
WO2000007629A2 (en) 2000-02-17
JP2013039139A (ja) 2013-02-28
HUP0103003A2 (hu) 2001-11-28
PL220873B1 (pl) 2016-01-29
BRPI9912974B8 (pt) 2021-05-25
HUP0103003A3 (en) 2006-04-28
JP2002522399A (ja) 2002-07-23
KR20010072287A (ko) 2001-07-31
EP1100542A2 (en) 2001-05-23
BR9912974A (pt) 2001-05-08
BRPI9917760B8 (pt) 2021-05-25
AU770014B2 (en) 2004-02-12
RU2004104953A (ru) 2005-07-27
RU2278680C2 (ru) 2006-06-27
TW570981B (en) 2004-01-11
RU2006107111A (ru) 2007-09-20
HU226294B1 (en) 2008-08-28
KR100488848B1 (ko) 2005-05-11
BR9917760B1 (pt) 2014-11-25

Similar Documents

Publication Publication Date Title
KR100614212B1 (ko) 피이지-유레이트 옥시데이즈 접합체 및 그의 이용
US9885024B2 (en) PEG-urate oxidase conjugates and use thereof
RU2443426C2 (ru) Конъюгаты уратоксидазы, фармацевтическая композиция для снижения уровней мочевой кислоты и способ получения вышеупомянутых конъюгатов
HK1037330B (en) Peg-urate oxidase conjugates and use thereof
HK1155080A (en) Isolated tetrameric uricase
HK1155080B (en) Isolated tetrameric uricase
HK1141738B (en) Peg-urate oxidase conjugates and use thereof
MXPA01001272A (en) Peg-urate oxidase conjugates and use thereof
HK1103303B (en) A method for isolating a tetrameric uricase

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20120725

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20130821

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20140724

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160727

Year of fee payment: 11

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20170728

Year of fee payment: 12

PR1001 Payment of annual fee

Fee payment year number: 12

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20180812

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180812

St.27 status event code: N-4-6-H10-H13-oth-PC1903

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000